Form 4: Catheter Precision CEO David Jenkins Acquires 450,000 Stock Options
SEC Form 4 Filing
David Jenkins, Chairman and CEO of Catheter Precision, Inc., reports the acquisition of 450,000 stock options on January 29, 2025.
Summary
- On January 29, 2025, David A. Jenkins, Chairman of the Board and CEO of Catheter Precision, Inc. (VTAK), acquired 450,000 stock options.
- The exercise price of these options is $0.42.
- The options vest in installments: 90,000 shares exercisable on January 29, 2025, 120,000 shares exercisable on January 29, 2026, 120,000 shares exercisable on January 29, 2027, and 120,000 shares exercisable on January 29, 2028.
- Following the transaction, Jenkins directly owns 450,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction filing. The option grant itself could be viewed as slightly positive, indicating alignment of management interests with shareholders, but the filing itself is simply a procedural disclosure.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the healthcare and medical device industry. Monitoring such filings provides insights into management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CEO aligns his interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of transaction and initial exercisability of 90,000 stock options. |
| 01/29/2026 | Exercisability of 120,000 stock options. |
| 01/29/2027 | Exercisability of 120,000 stock options. |
| 01/29/2028 | Exercisability of 120,000 stock options. |
| 01/29/2035 | Expiration date of the stock options. |
| 01/31/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, VTAK, Catheter Precision, David Jenkins, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.